ICUI

Business Context and Reporting Period

Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1998
Business Overview: The company manufactures and sells medical products, primarily needleless connectors (CLAVE), protected needles, and custom I.V. sets. Sales are driven by strategic agreements with major distributors B.Braun/McGaw and Abbott Laboratories, alongside independent distributors.

Key Financial Metrics

Note: Balance sheet data for Q1 1997 is not provided in the text; comparisons are made to Q1 1997 income statement figures where available.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 46% ($3.16 million) year-over-year, driven primarily by a 53% increase in CLAVE product sales.
• Customer Concentration: Sales to Abbott Laboratories surged to $2.7 million (from $0.6 million in Q1 1997). Sales to B.Braun/McGaw increased to $3.3 million (from $2.8 million).
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 84% to $3.17 million. This was largely due to a spike in patent litigation costs ($425,000 vs. $67,000) and investments in the Budget Medical Products (BMP) business.
• Cash Flow: Net cash provided by operating activities decreased to $1.31 million from $1.86 million, despite higher net income, due to increased working capital requirements (inventory and receivables).
• Investing Activity: Significant capital expenditures of $1.73 million were incurred, compared to $0.13 million in the prior year, related to facility expansion and automation.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Sales Trends: Management expects CLAVE unit shipments to B.Braun/McGaw and Abbott to continue increasing through 1998. However, average selling prices are expected to decline due to market pressure and a shift toward bulk, non-sterile sales.
• Product Mix: Sales of legacy products (Click Lock and Piggy Lock) are expected to decline as the market shifts to needleless technology. The new CLC 2000 connector began shipments in Q2 1998.
• Capital Expenditures: Significant increases in CapEx are planned for 1998 to automate production and build a new facility in Mexico for BMP operations.
• Liquidity: Management believes existing working capital and operating income will be sufficient for the foreseeable future.

Risks and Contingencies

• Legal Proceedings:
  • ICU Medical v. Tri-State Hospital Supply: Trial set for June 1, 1998. Company seeks injunction and damages.
  • Allen Petty v. ICU Medical: A jury verdict of $795,448 was rendered against the company in April 1998. Management intends to appeal and has not accrued the loss, believing they will prevail.
• Distribution Risks: The European distribution agreement with BOC OHMEDA AB is expected to terminate in August 1998. The company is seeking alternative arrangements but notes no assurance of success.
• Customer Concentration: A significant portion of revenue relies on a small number of customers (B.Braun/McGaw and Abbott). Loss of these contracts would materially adversely affect results.
• Competition: Competitors are developing similar one-piece needleless connectors, leading to price erosion.

Investor Verification Checklist

• Legal Exposure: Verify the status of the $795,448 verdict in the Allen Petty case and the potential financial impact of the pending patent trial against Tri-State Hospital Supply.
• European Distribution: Confirm the status of replacement distribution agreements in Europe following the termination of the Ohmeda contract in August 1998.
• Margin Sustainability: Monitor whether increased production volume continues to offset declining average selling prices to maintain the 58% gross margin.
• Contract Renewals: Track the finalization of the modified agreement with B.Braun/McGaw, as current pricing is based on a letter of intent.
• CapEx Execution: Assess the progress and cost overruns related to the new manufacturing facility in Mexico and production automation.